Full Press Release Details
Sunesis Pharmaceuticals Reports Fourth Quarter and
Full-Year 2010 Financial Results
SOUTH SAN FRANCISCO, Calif., March 29, 2011 Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today reported financial results for the fourth quarter and year ended December 31, 2010.
Net loss for the three months and year ended December 31, 2010 was $10.1 million and $24.6 million, respectively. As of December 31, 2010, cash, cash equivalents and marketable securities totaled $53.4 million, with no debt outstanding.
This past year was a landmark year for Sunesis, with our lead program, vosaroxin, moving into a pivotal Phase 3 trial, the VALOR trial,
in acute myeloid leukemia, said Daniel Swisher, Chief Executive Officer of Sunesis. Since the beginning of the fourth quarter, we achieved a number of critical clinical, regulatory, intellectual property and financial objectives,
including the launch of the VALOR trial. I am pleased with the pace of site activation and patient enrollment to date. With an improved capital structure and over $53 million in cash at the end of 2010, Sunesis is today well positioned to reach our
goals of bringing an important new cancer treatment to patients with an enduring unmet need.
Fourth Quarter 2010 and Recent
Financial Highlights
VALOR is a Phase 3, randomized, double-blind, placebo-controlled, pivotal trial in patients with first relapsed or refractory AML. The trial is expected to enroll 450 evaluable patients at approximately
100 leading sites in the U.S., Canada, Europe, Australia and New Zealand. The VALOR trial is currently open for enrollment and patients will be randomized one to one to receive either vosaroxin on days one and four in combination with cytarabine
daily for five days, or placebo in combination with cytarabine. Additionally, the VALOR trial employs an innovative, adaptive trial design that allows for a one-time sample size adjustment by the DSMB at the interim analysis to maintain adequate
power across a broad range of clinically meaningful and statistically significant survival outcomes. The trial s primary endpoint is overall survival. For more information on the VALOR trial, please visit www.valortrial.com.
About Vosaroxin (Formerly Voreloxin)
Vosaroxin is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer.
Vosaroxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis.
About Acute Myeloid Leukemia
AML is a rapidly progressing cancer of the blood
characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The American Cancer Society estimated that 12,330 new cases of AML will be diagnosed and approximately 9,000 deaths from AML will occur in the U.S. in 2010.
Additionally, it is estimated that prevalence of AML is approximately 25,000 in the U.S. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. AML patients with relapsed or refractory
disease and newly diagnosed AML patients over 60 years of age with poor prognostic risk factors typically die within one year, resulting in an acute need for new treatment options for these patients.
About Sunesis Pharmaceuticals
is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to
advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis, please visit www.sunesis.com.
This press release contains forward-looking statements, including statements related to the sufficiency of Sunesis cash resources, the design,
conduct and results of the VALOR trial, the prosecution of patent applications with the EPO and vosaroxin s effects, efficacy and safety profile as a single agent and in combination with cytarabine. Words such as well positioned,
expected, to date, could, pending and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis current expectations.
Forward-looking statements involve risks and uncertainties. Sunesis actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a results of these risks and uncertainties, which
include, without limitation, risks related to Sunesis need for substantial additional funding to complete the development and commercialization of vosaroxin, risks related to Sunesis ability to raise the capital that it believes to be
accessible and is required to fully finance the VALOR trial until its
planned unblinding in 2013, the risk that Sunesis development activities for vosaroxin could be otherwise halted or significantly delayed for various reasons, the risk that Sunesis
clinical studies for vosaroxin may not demonstrate safety or efficacy or lead to regulatory approval, the risk that data to date and trends may not be predictive of future data or results, the risk that Sunesis nonclinical studies and clinical
studies may not satisfy the requirements of the FDA or other regulatory agencies, risks related to the conduct of Sunesis clinical trials, risks related to the manufacturing of vosaroxin and supply of the active pharmaceutical ingredients
required for the conduct of the VALOR trial, the risk of third party opposition to granted patents related to vosaroxin, and the risk that Sunesis proprietary rights may not adequately protect vosaroxin. These and other risk factors are
discussed under Risk Factors and elsewhere in Sunesis Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 and Sunesis other filings with the Securities and Exchange Commission, including Sunesis
Annual Report on Form 10-K for the year ended December 31, 2010 when available. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect
any change in the company s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.
SUNESIS PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEETS
| December 31, 2010 | December 31, 2009 | |||||||
| (Unaudited) | (Note 1) | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 14,223,388 | $ | 4,258,715 | ||||
| Marketable securities | 39,172,480 | |||||||
| Prepaids and other current assets | 1,285,487 | 583,030 | ||||||
| Total current assets | 54,681,355 | 4,841,745 | ||||||
| Property and equipment, net | 116,188 | 263,111 | ||||||
| Deposits and other assets | 59,974 | 64,425 | ||||||
| Total assets | $ | 54,857,517 | $ | 5,169,281 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 415,802 | $ | 360,300 | ||||
| Accrued clinical expense | 1,573,580 | 1,129,226 | ||||||
| Accrued compensation | 1,013,240 | 728,744 | ||||||
| Other accrued liabilities | 1,380,409 | 788,559 | ||||||
| Current portion of deferred rent | 26,267 | 27,943 | ||||||
| Warrant liability | 8,153,712 | |||||||
| Total current liabilities | 12,563,010 | 3,034,772 | ||||||
| Non-current portion of deferred rent | 47,838 | 74,105 | ||||||
| Commitments | ||||||||
| Stockholders equity: | ||||||||
| Convertible preferred stock | 60,004,986 | |||||||
| Common stock | 4,537 | 3,590 | ||||||
| Additional paid-in capital | 423,262,099 | 298,469,584 | ||||||
| Accumulated other comprehensive loss | (14,726 | ) | ||||||
| Accumulated deficit | (381,005,241 | ) | (356,417,756 | ) | ||||
| Total stockholders equity | 42,246,669 | 2,060,404 | ||||||
| Total liabilities and stockholders equity | $ | 54,857,517 | $ | 5,169,281 |
Note 1: The consolidated balance sheet as of December 31, 2009 has been derived from the audited financial statements
as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2009.
SUNESIS PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
| Three months ended December 31, | Year ended December 31, | |||||||||||||||
| 2010 | 2009 | 2010 | 2009 | |||||||||||||
| (Unaudited) | (Unaudited) | (Note 2) | ||||||||||||||
| Revenue: | ||||||||||||||||
| Collaboration revenue | $ | $ | 12,500 | $ | 27,083 | $ | 1,550,000 | |||||||||
| License and other revenue | 6,000 | 6,000 | 2,211,547 | |||||||||||||
| Total revenues | 6,000 | 12,500 | 33,083 | 3,761,547 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 4,874,007 | 2,178,045 | 14,433,777 | 13,246,859 | ||||||||||||
| General and administrative | 1,785,201 | 1,864,960 | 7,004,909 | 7,748,243 | ||||||||||||
| Restructuring charges | (18,451 | ) | 1,915,316 | |||||||||||||
| Total operating expenses | 6,659,208 | 4,024,554 | 21,438,686 | 22,910,418 | ||||||||||||
| Loss from operations | (6,653,208 | ) | (4,012,054 | ) | (21,405,603 | ) | (19,148,871 | ) | ||||||||
| Other income (expense), net | (3,418,614 | ) | (23,018 | ) | (3,181,882 | ) | (21,077,175 | ) | ||||||||
| Net loss | (10,071,822 | ) | (4,035,072 | ) | (24,587,485 | ) | (40,226,046 | ) | ||||||||
| Deemed distribution to preferred stockholders | (1,188,400 | ) | (27,563,400 | ) | ||||||||||||
| Loss attributable to common stockholders | $ | (10,071,822 | ) | $ | (5,223,472 | ) | $ | (24,587,485 | ) | $ | (67,789,446 | ) | ||||
| Basic and diluted loss attributable to common stockholders per common share | $ | (0.23 | ) | $ | (0.90 | ) | $ | (0.99 | ) | $ | (11.80 | ) | ||||
| Shares used in computing basic and diluted loss attributable to common stockholders per common share | 43,879,448 | 5,779,792 | 24,860,212 | 5,746,786 |
Note 2: The consolidated statement of
operations for the year ended December 31, 2009 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2009.